Castle Biosciences, Inc. (CSTL) Unveils Largest Real-World Melanoma Risk Study at ASCO 2025

By Yahoo! Finance   |   1 month ago
Castle Biosciences, Inc. (CSTL) Unveils Largest Real-World Melanoma Risk Study at ASCO 2025

Castle Biosciences presents data at ASCO 2025 on DecisionDx-Melanoma test, showing 32% mortality risk reduction in cutaneous melanoma patients.

Read More

Did you find this insightful?